- Home
- BRTX vs EDSA Comparison
BRTX vs EDSA Comparison
Compare BRTX & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRTX
- EDSA
- Stock Information
- Founded
- BRTX 1997
- EDSA 2015
- Country
- BRTX United States
- EDSA Canada
- Employees
- BRTX N/A
- EDSA N/A
- Industry
- BRTX Managed Health Care
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- BRTX Health Care
- EDSA Health Care
- Exchange
- BRTX Nasdaq
- EDSA Nasdaq
- Market Cap
- BRTX 12.6M
- EDSA 13.8M
- IPO Year
- BRTX N/A
- EDSA N/A
- Fundamental
- Price
- BRTX $1.61
- EDSA $2.05
- Analyst Decision
- BRTX Strong Buy
- EDSA Strong Buy
- Analyst Count
- BRTX 1
- EDSA 2
- Target Price
- BRTX $18.00
- EDSA $13.00
- AVG Volume (30 Days)
- BRTX 253.7K
- EDSA 33.4K
- Earning Date
- BRTX 08-12-2025
- EDSA 08-08-2025
- Dividend Yield
- BRTX N/A
- EDSA N/A
- EPS Growth
- BRTX N/A
- EDSA N/A
- EPS
- BRTX N/A
- EDSA N/A
- Revenue
- BRTX $391,000.00
- EDSA N/A
- Revenue This Year
- BRTX $391.52
- EDSA N/A
- Revenue Next Year
- BRTX $3.50
- EDSA N/A
- P/E Ratio
- BRTX N/A
- EDSA N/A
- Revenue Growth
- BRTX 161.54
- EDSA N/A
- 52 Week Low
- BRTX $1.21
- EDSA $1.55
- 52 Week High
- BRTX $2.55
- EDSA $5.59
- Technical
- Relative Strength Index (RSI)
- BRTX 46.78
- EDSA 52.89
- Support Level
- BRTX $1.57
- EDSA $1.91
- Resistance Level
- BRTX $1.72
- EDSA $2.14
- Average True Range (ATR)
- BRTX 0.13
- EDSA 0.12
- MACD
- BRTX -0.01
- EDSA 0.02
- Stochastic Oscillator
- BRTX 20.65
- EDSA 64.52
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.